Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Outcomes for patients with advanced or metastatic Bladder Cancer remain poor.
Targeting the programmed death ligand-1 (PD-(L)1) immune checkpoint pathway has emerged as a valid target in patients with Bladder Cancer.
Treatment options for metastatic Bladder Cancer have increased dramatically over the past decade.
Meza et al. 2022 Future Oncology 18: 21-33
In the past few years, several new agents have been approved for the treatment of urothelial tumors.
Metastatic bladder cancer has historically been treated with first-line platinum-based combination chemotherapy, preferably [cisplatin plus gemc…